SMITHS GROUP SERVICES CORPORATION for SMITHS GROUP SERVICES CORPORATION
What was lobbied
8 issue areas, each in the filer's own words, with who lobbied on it and where.
Environment/Superfund ENV
Issues related to climate change and emissions technologies. Issues related to mechanical seals emissions technologies and energy infrastructure. Issues related to PFAS.
Foreign entity interest: Smiths Group plc -- the parent company of the registrant has interest in all activities of the registrant
| Lobbyist | Covered position, as disclosed |
|---|---|
| LISA CEGLIA | — |
Trade (domestic/foreign) TRD
General trade discussions including Section 301 and Section 232 tariffs. Issues related to the United States-Mexico-Canada Agreement (P.L.116-113).
Foreign entity interest: Smiths Group plc -- the parent company of the registrant has interest in all activities of the registrant
| Lobbyist | Covered position, as disclosed |
|---|---|
| LISA CEGLIA | — |
Defense DEF
Issues related to CBRNE (Chemical, Biological, Radiological, Nuclear and Explosives) technology, detection solutions for the Department of Defense, and Navy RDT&E and Ship Equipment; FY2021 Department of Defense Appropriations Act (H.R.7617/Senate) and FY2021 National Defense Authorization Act (H.R.6395/S.4049).
Foreign entity interest: Smiths Group plc -- the parent company of the registrant has interest in all activities of the registrant
| Lobbyist | Covered position, as disclosed |
|---|---|
| LISA CEGLIA | — |
| KEVIN SCHMIDT | — |
Budget/Appropriations BUD
Funding for aviation security and homeland security technologies. H.R.1171, Funding for Aviation Screeners and Threat Elimination Restoration Act (FASTER Act); aviation security fees. Monitored applicable FY2020 appropriations bills. FY2021 Department of Homeland Security Appropriations Act (H.R.7669/Senate); Transportation Security Administration (TSA) funding. FY2021 Department of Defense Appropriations Act (H.R.7617/Senate); Chemical Bio Funding; Navy RDT&E. FY2021 Commerce, Justice, Science, and Related Agencies Appropriations Act (H.R.7667/Senate); Opioid Funding. FY2021 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act (H.R.7614/Senate); Reimbursement for Medical Devices. H.R.7617, FY2021 Consolidated Appropriations Act. FY2021 National Defense Authorization Act (H.R.6395/S.4049). H.R.6800, Health and Economic Recovery Omnibus Emergency Solutions Act, HEROES Act. The Health, Economic Assistance, Liability Protection and Schools Act, HEALS Act (Senate proposed legislation).
Foreign entity interest: Smiths Group plc -- the parent company of the registrant has interest in all activities of the registrant
| Lobbyist | Covered position, as disclosed |
|---|---|
| LISA CEGLIA | — |
| KEVIN SCHMIDT | — |
Aviation/Airlines/Airports AVI
Aviation security solutions and detection technologies for the Transportation Security Administration (TSA). FY2020/FY2021 DHS Authorization. Aviation security fees; H.R.1171, Funding for Aviation Screeners and Threat Elimination Restoration Act (FASTER Act).
Foreign entity interest: Smiths Group plc -- the parent company of the registrant has interest in all activities of the registrant
| Lobbyist | Covered position, as disclosed |
|---|---|
| KEVIN SCHMIDT | — |
Homeland Security HOM
Issues related to aviation security solutions and detection technologies for the Transportation Security Administration (TSA), Department of Homeland Security (DHS), U.S. Customs and Border Protection (CBP) and the Domestic Nuclear Detection Office (DNDO). Issues related to CBRNE (Chemical, Biological, Radiological, Nuclear and Explosives) technology and other border security solutions. TSA funding and aviation security fees generally. FY2021 Department of Homeland Security Appropriations Act (H.R.7669/Senate). Implementation of SUPPORT for Patients and Communities Act (P.L.115-271), law enforcement grants.
Foreign entity interest: Smiths Group plc -- the parent company of the registrant has interest in all activities of the registrant
| Lobbyist | Covered position, as disclosed |
|---|---|
| KEVIN SCHMIDT | — |
Medical/Disease Research/Clinical Labs MED
Issues related to patient infusion therapy, Medicare reimbursements for tracheotomy tubes, reimbursement/policy issues related to opioid alternative treatments, medical device technology related to the opioid epidemic and the COVID-19 pandemic. Implementation of the 21st Century Cures Act (P.L.114-255). Implementation of Medicare Part B Home Infusion Services Temporary Transitional Payment Act. H.R.5172/S.3067, NOPAIN Act. Federal COVID response, including Coronavirus Aid, Relief, and Economic Security (CARES) Act (P.L.116-136).
Foreign entity interest: Smiths Group plc -- the parent company of the registrant has interest in all activities of the registrant
| Lobbyist | Covered position, as disclosed |
|---|---|
| LISA CEGLIA | — |
Torts TOR
General issues related to tort reform and minimal diversity jurisdiction. Civil liability issues in possible COVID related legislation.
Foreign entity interest: Smiths Group plc -- the parent company of the registrant has interest in all activities of the registrant
| Lobbyist | Covered position, as disclosed |
|---|---|
| LISA CEGLIA | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.